The market for stereotactic radiation therapy will expand considerably during the period from 2025 through 2035 because healthcare institutions continue to favour precise non-invasive treatment options for cancer and adopt state-of-the-art radiotherapy technologies.
SRT provides targeted delivery of strong radiation beams to tumors which preserves nearby healthy tissue so medical professionals prefer this treatment for localized cancers found in brain tissue as well as lung tissue spine tissue and liver tissue. The forecast shows SRT market reaching USD 9,076 million by 2035 from its initial value of USD 4,570.8 million in 2025 which creates a 7.1% Compound Annual Growth Rate (CAGR).
Nowadays SRT's clinical applications are growing while its treatment accuracy improves because of advancements such as image-guided radiotherapy (IGRT) and motion tracking and robotic precision systems. Healthcare providers are growing their SRS and SBRT system investments because of both rising cancer numbers and increasing need for outpatient-based care.
Treatment duration preferences along with improved quality of life outcomes from patients have driven providers to adopt SRT as a treatment approach. SRT remains crucial for personalized oncology treatment because it continues to advance cancer treatments in integrated healthcare settings throughout hospitals and specialty cancer facilities.
Key Market Metrics
| Metric | Value |
|---|---|
| Industry Size (2025E) | USD 4,570.8 million |
| Industry Value (2035F) | USD 9,076 million |
| CAGR (2025 to 2035) | 7.1% |
Explore FMI!
Book a free demo
The North American market holds the largest position in stereotactic radiation therapy because of its developed oncology framework coupled with robust payment systems and intensive radiotherapy research investments. SRT systems enter mainstream usage in Canadian and American leading cancer centers to treat malignant tumors more precisely through a reduced treatment process.
The European market demonstrates consistent expansion while Germany, United Kingdom and France enact stereotactic integration within their medical oncology treatments. Cross-sectoral healthcare adoption of precise medicine receives governmental backing and rising non-surgical cancer knowledge which accelerates implementation throughout public and private healthcare.
Speedy expansion in cancer occurrences together with expanding radiotherapy service availability and investment into contemporary treatment machinery makes Asia-Pacific a rapidly expanding territory. Stereotactic technology integration forms part of cancer care systems in China together with Japan and South Korea and India as these countries focus on minimizing treatment duration while optimizing patient results.
High Equipment Costs and Technical Expertise Requirements
The stereotactic radiation therapy market is under pressure due to high costs associated with advanced radiotherapy systems and special training to operate them. For example, stereotactic body radiation therapy (SBRT) and stereotactic radiosurgery (SRS) need submillimetre precision from highly sophisticated imaging, motion-tracking, and treatment planning systems. High-end systems and costs make these services less accessible in poorer regions and smaller oncology centers.
Adoption delay is also caused by reimbursement limitations and lengthy approval times for new indications. Thus, SRT becomes limited in use to tertiary and academic care centers, while clinical advantages in treatment precision for localized tumors are denied patients. Opportunity: Increased Need for High-Precision Non-Invasive Cancer Therapy
Rising Demand for Non-Invasive, High-Precision Cancer Treatment
Stereotactic radiation therapy is growing despite these hurdles since it caters to the increasing demand for non-invasive organ-preserving cancer treatments. A higher patient convenience and decreased visits to hospitals should be achieved, which is essential to the older population and disruptive health care where ablative doses of radiation are given in fewer sessions.
This highlights the application of this technique in brain metastases, small lung cancers, liver tumors, and spine lesions. Ongoing developments in AI-guided planning, image-guided delivery, and integration with MR-linacs will ensure much improved accuracy and safety for the treatments. As the clinical guidelines will expand to cover more tumor types, SRT will become the base of curative radiotherapy with the least amount of toxicity because it is treating the majority of patients.
Between the years 2020 and 2024, SRT developed substantially in high-volume cancer centers, especially directed at brain and lung tumor patients. Its technological choices focused on linear accelerators with image-guided radiation therapy (IGRT) and robotic systems, such as CyberKnife.
From 2025 to 2035, the market will migrate toward AI-enhanced adaptive stereotactic radiation therapy, MR-guided systems, and into outpatient and community-based cancer care. Real-time tumor motion tracking, cloud-based treatment planning, and integration with immuno-oncology protocols are all set to uplift the future outcomes and extend the clinical utility for stereotactic radiation therapy in the worldwide arena.
Market Shifts: Comparative Analysis (2020 to 2024 vs. 2025 to 2035)
| Market Factor | 2020 to 2024 |
|---|---|
| Regulatory Landscape | Approval for localized tumors (e.g., brain, lung, spine). |
| Technological Advancements | IGRT, cone-beam CT, and robotic-arm accelerators. |
| Sustainability Trends | Focus on reducing treatment fractions and facility time. |
| Market Competition | Led by radiotherapy system manufacturers and academic oncology centers. |
| Industry Adoption | Common in tertiary oncology centers and academic hospitals. |
| Consumer Preferences | Focused on non-invasive treatment with fewer sessions. |
| Market Growth Drivers | Boosted by early-stage cancer detection and demand for precision care. |
| Market Factor | 2025 to 2035 |
|---|---|
| Regulatory Landscape | Expansion to early-stage and oligometastatic cancers with precision medicine alignment. |
| Technological Advancements | Rise of MR-guided radiotherapy, AI-based planning, and real-time adaptive treatment. |
| Sustainability Trends | Shift to outpatient SRT, energy-efficient systems, and reusable immobilization accessories. |
| Market Competition | Entry of AI-radiotherapy startups and integrated cancer therapy platform providers. |
| Industry Adoption | Expands to regional cancer networks, ambulatory radiotherapy units, and global tele-radiotherapy models. |
| Consumer Preferences | Shift to personalized, image-adaptive, and immuno-radiotherapy-integrated solutions. |
| Market Growth Drivers | Accelerated by AI innovations, aging population, and expansion of radiation oncology infrastructure. |
The rising acceptance of SRS (Stereotactic Radiosurgery) and SBRT (Stereotactic Body Radiotherapy) for early and inoperable cancers is fuelling the robust growth of the stereotactic radiation therapy market in the USA Cancer centers are investing considerable amounts in next-gen linear accelerators, image-guidance systems, and motion-management technologies.
Reimbursement policies and expanded indications have also made SRT a key feature in outpatient oncology for lung, liver, and prostate tumors.
| Country | CAGR (2025 to 2035) |
|---|---|
| USA | 7.0% |
In the UK, constant improvement is being observed in the market due to facility upgrades by NHS and increasing preference of clinicians toward stereotactic techniques in treating small and localized tumors.
SBRT is gaining popularity in oligometastatic disease and functional brain disorders, with government funding under the Cancer Strategy promoting access to high-precision treatment technologies.
| Country | CAGR (2025 to 2035) |
|---|---|
| UK | 6.9% |
In the European Union, especially Germany, France, and Sweden, strong growth for SRT development is ongoing. Robotic radiosurgery and frameless stereotactic systems are being embraced by both public and private oncology centers to spare healthy tissues and optimize treatment outcomes.
Radiotherapy firms in the EU are also pioneers in software innovations promoting adaptive planning and automated dose delivery systems in support of personalized SRT.
| Region | CAGR (2025 to 2035) |
|---|---|
| European Union | 7.1% |
The market for stereotactic radiation therapy in Japan is on a steady path of evolution, sufficient to support fast cancer screening programs and early adoption of robotic radiosurgery systems. Japanese hospitals use SRS and SBRT for brain and thoracic tumors with submillimetre accuracy.
Domestic technology companies keep developing compact linear accelerators and advanced imaging modules to allow for better accessibility to SRT even in regional hospitals.
| Country | CAGR (2025 to 2035) |
|---|---|
| Japan | 7.0% |
Korea finds an SRT market moving along fast due to a rise in cancer cases, enhanced reimbursement coverage, and enhanced outpatient offering for radiotherapy services. Leading hospitals implement advanced beam delivery platforms integrating MRI and PET imaging for accurate tumor localization.
The government's push for medical innovation and export-ready healthcare infrastructure is leading to an increase in SRT demand from public and private institutions.
| Country | CAGR (2025 to 2035) |
|---|---|
| South Korea | 7.5% |
The market flow for stereotactic radiation therapy (SRT) is, indeed, experiencing a phenomenal growth trend primarily due to increasing incidents of cancer cases, the trend toward noninvasive treatments, and technological innovations in image-guided radiation.
SRT precisely delivers high radiation doses to a target while minimizing collateral and accidental damage to the healthy surrounding tissue. Among the advanced technologies, CyberKnife systems are the market leaders when it comes to robotic precision, real-time tracking, and frameless patient setup.
Next to these very latest delivery systems, lung cancer is the most frequently implied condition for SRT, with most patients opting for a treatment alternative to surgery or standard fractionated radiation in the majority of early-stage and inoperable instances.
At present, both sectors are poised at the forefront of clinical adoption, technological innovation, and therapeutic impact for modern cancer care package as the health systems further cement investments in advanced oncology solutions.
| Technology Type | Market Share (2025) |
|---|---|
| CyberKnife | 38.4% |
The market leadership of CyberKnife systems within the technology sector comes from their unmatched tracking capabilities combined with real-time motion assessment which delivers precise tumor treatment in difficult anatomical locations.
The robotic arm of CyberKnife delivers radiation through multiple angles by means of sophisticated image guidance that automatically adjusts treatment position even during breathing cycles. Healthcare providers choose CyberKnife to treat sensitive lesions throughout the lung as well as spine and brain and prostate areas since exact treatment and patient movement adjustment requirements are fundamental therapeutic elements.
The development of latest CyberKnife systems includes sophisticated artificial intelligence programs that pair with adaptive treatment planning systems and connection to both MRI and PET imaging infrastructure. The systems enable doctors to apply treatment to tumors which were unreachable due to critical structure positioning.
Through hypofractionation treatment CyberKnife provides patients with better convenience and better healthcare center productivity. The increase in outpatient cancer treatment requests makes CyberKnife a fundamental force behind stereotactic radiation therapy market growth which positions it as an innovation leader in this field.
| Indication Type | Market Share (2025) |
|---|---|
| Lung Cancer | 42.1% |
The indication segment of stereotactic radiation therapy is led by lung cancer because physicians choose precise non-invasive treatment methods for patients who cannot have surgery or refuse it. The implementation of stereotactic body radiation therapy (SBRT) as part of SRT technology has become very effective against early-stage non-small cell lung cancer and achieves local control outcomes at surgical levels. SRT's single-session or five-session delivery of ablative doses increases its appeal for medically weak patients and the elderly population.
SRT therefore seems to offer the most advantages to radiation oncologists, as it has lesser toxicity and requires a shorter time for treatment than any other therapeutic option. The tumour’s targeting using modern innovative technologies like CyberKnife or image-guided linear accelerator leads to an optimized exposure of non-target lung tissues and thereby reduced probability of radiation pneumonitis.
The incidence has increased sharply across world populations because there is still more tobacco and air pollution in the current globalized society, causing many health-care providers to turn to SR-T as a safe, effective, and well-tolerated alternative to invasive treatment. So, the up-scaling of SRT will ensure that lung cancer will constantly add to the revenues growth propelled by market intervention.
The global stereotactic radiation therapy (SRT) market is a highly specialized and technologically advanced segment of oncology care, delivering precise, high-dose radiation to small, well-defined tumors using stereotactic techniques.
It includes stereotactic radiosurgery (SRS), primarily used for intracranial lesions, and stereotactic body radiotherapy (SBRT), used for extracranial tumors in the lung, liver, spine, and prostate. SRT enables non-invasive tumor ablation while sparing surrounding healthy tissue, making it ideal for treating inoperable or recurrent cancers.
Market growth is driven by the increasing incidence of cancer, expanding indications for SBRT, and the development of image-guided radiotherapy platforms. Key players compete on imaging integration, real-time tracking, beam delivery precision, automation, and clinical data supporting hypofractionated treatment protocols.
Market Share Analysis by Company
| Company Name | Estimated Market Share (%) |
|---|---|
| Elekta AB | 28-32% |
| Varian Medical Systems (Siemens Healthineers) | 24-28% |
| Accuray Incorporated | 14-18% |
| Brainlab AG | 9-13% |
| ViewRay, Inc. | 6-10% |
| Other Companies (combined) | 12-17% |
| Company Name | Key Offerings/Activities |
|---|---|
| Elekta AB | Markets the Elekta Unity® MR-Linac and Leksell Gamma Knife® platforms for SRS and SBRT with adaptive imaging and precision dose sculpting in 2025. |
| Varian Medical Systems | Provides the TrueBeam® and Edge™ platforms with HyperArc™ SRS and advanced SBRT protocols, integrated with ARIA® oncology information system in 2024. |
| Accuray Incorporated | Offers the CyberKnife® system for robotic SRT with real-time tumor tracking and automated beam delivery in both intracranial and extracranial tumors in 2025. |
| Brainlab AG | Develops ExacTrac® Dynamic and Elements™ software suite for frameless SRS/SBRT planning and motion monitoring, often used in hybrid radiotherapy systems in 2024. |
| ViewRay, Inc. | Released MRIdian® Linac, combining real-time MRI guidance with high-precision SBRT, enabling adaptive radiation therapy for soft tissue tumors in 2024. |
Key Company Insights
Elekta AB
Elekta is a global leader in both intracranial and extracranial stereotactic radiotherapy, with Unity® offering MRI-guided adaptive therapy and Gamma Knife® setting the standard in cranial SRS. Its systems are favored for treatment accuracy, real-time imaging, and workflow automation.
Varian Medical Systems (Siemens Healthineers)
Varian leads in comprehensive SBRT delivery through TrueBeam® and Edge™, featuring HyperArc™ for ultra-conformal radiosurgery. Integration with Siemens imaging technologies and oncology software enhances its dominance in high-volume cancer centers.
Accuray Incorporated
Accuray’s CyberKnife® platform offers unparalleled flexibility in non-invasive SRT, utilizing robotic arms for sub-millimeter precision and motion synchronization. It is widely used in prostate, lung, and spinal tumor ablation.
Brainlab AG
Brainlab is known for software-driven stereotactic platforms, providing imaging, positioning, and adaptive planning tools. Its ExacTrac® systems are often integrated with third-party linacs, enhancing the precision of multi-modality SRT procedures.
ViewRay, Inc.
ViewRay is pioneering real-time MRI-guided radiotherapy with MRIdian®, allowing continuous tumor visualization during treatment. Its adaptive workflows improve outcomes in soft tissue cancers where motion and anatomical variability are concerns.
Other Key Players (12-17% Combined)
Several emerging tech developers and regional radiation therapy providers contribute to the SRT market with niche innovations and accessible systems for mid-tier healthcare networks:
The overall market size for the stereotactic radiation therapy market was USD 4,570.8 million in 2025.
The stereotactic radiation therapy market is expected to reach USD 9,076 million in 2035.
The increasing incidence of early-stage and inoperable cancers, rising adoption of non-invasive precision therapies, and growing deployment of CyberKnife systems for lung cancer indications fuel the stereotactic radiation therapy market during the forecast period.
The top 5 countries driving the development of the stereotactic radiation therapy market are the USA, UK, European Union, Japan, and South Korea.
CyberKnife systems and lung cancer indications lead market growth to command a significant share over the assessment period.
Stereotactic Radiation Therapy Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
